116 related articles for article (PubMed ID: 4039775)
21. Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis.
Agostinucci WA; Gannon RH; Golub GR; Martin RS; Schauer PK; Dinonno EB
Clin Pharm; 1988 Jun; 7(6):454-7. PubMed ID: 3402181
[TBL] [Abstract][Full Text] [Related]
22. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
Warrington PS; Allan SG; Cornbleet MA; MacPherson JS; Smyth JF; Leonard RC
Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1334-7. PubMed ID: 3790968
[TBL] [Abstract][Full Text] [Related]
23. [Recent advances in the management of chemotherapy-induced emesis].
Murakami M; Ota K
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):401-11. PubMed ID: 3006594
[TBL] [Abstract][Full Text] [Related]
24. Metoclopramide. A review of antiemetic trials.
Gralla RJ
Drugs; 1983 Feb; 25 Suppl 1():63-73. PubMed ID: 6682376
[TBL] [Abstract][Full Text] [Related]
25. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
26. A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin.
Parikh PM; Charak BS; Banavali SD; Koppikar SB; Giri N; Nadkarni P; Saikia TK; Gopal R; Advani SH
Cancer; 1988 Nov; 62(10):2263-6. PubMed ID: 3052785
[TBL] [Abstract][Full Text] [Related]
27. Antiemetic effects of metoclopramide (M) continuous infusion (CI): safety, efficacy, patient preference, and cost reduction.
Presant CA; Wiseman C; Gala K; Kennedy P; Bouzaglou A; Blayney D; Schindler J; Rigas M; Melville J; Dolan J
Prog Clin Biol Res; 1987; 248():299-302. PubMed ID: 3671417
[No Abstract] [Full Text] [Related]
28. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
[TBL] [Abstract][Full Text] [Related]
29. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Sledge GW; Einhorn L; Nagy C; House K
Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
[TBL] [Abstract][Full Text] [Related]
30. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
[TBL] [Abstract][Full Text] [Related]
31. Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison.
Malone JM; Christensen CW; Yashinsky D; Malviya VK; Deppe G
J Reprod Med; 1990 Oct; 35(10):932-4. PubMed ID: 2246759
[TBL] [Abstract][Full Text] [Related]
32. The effect of administration rate on cisplatin-induced emesis.
Jordan NS; Schauer PK; Schauer A; Nightingale C; Golub G; Martin RS; Williams HM
J Clin Oncol; 1985 Apr; 3(4):559-61. PubMed ID: 3884747
[TBL] [Abstract][Full Text] [Related]
33. The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial.
O'Brien ME; Cullen MH; Woodroffe C; Kelly K; Burman C; Palmer K; Stuart NS; Blackledge GR; Sharpe J
Br J Cancer; 1989 Nov; 60(5):759-63. PubMed ID: 2679853
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial comparing two short courses of moderate-dose metoclopramide for moderate-dose cisplatin-induced emesis.
Pollera CF; Conti EM; De Nigris A; Calabresi F
Oncology; 1987; 44(2):73-7. PubMed ID: 3554084
[TBL] [Abstract][Full Text] [Related]
35. Antiemetic efficacy of moderately high-dose metoclopramide in patients receiving varying doses of cisplatin. Controlled comparison with a combination of methylprednisolone and metoclopramide.
Ell C; König HJ; Brockmann P; Domschke S; Domschke W
Oncology; 1985; 42(6):354-7. PubMed ID: 4069550
[TBL] [Abstract][Full Text] [Related]
36. High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma.
Onsrud M; Moxnes A; Sollien A; Grande T; Solesvik O
Cancer; 1988 Jun; 61(12):2429-32. PubMed ID: 3365665
[TBL] [Abstract][Full Text] [Related]
37. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.
Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tamura T; Fujiwara Y; Mae M; Fukuda M; Ohe Y; Sasaki S
Jpn J Clin Oncol; 1989 Mar; 19(1):40-4. PubMed ID: 2921817
[TBL] [Abstract][Full Text] [Related]
38. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
39. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation.
Strum SB; McDermed JE; Pileggi J; Riech LP; Whitaker H
Cancer; 1984 Mar; 53(6):1432-9. PubMed ID: 6692333
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin-induced emesis in the Ferret: a new animal model.
Florczyk AP; Schurig JE; Bradner WT
Cancer Treat Rep; 1982 Jan; 66(1):187-9. PubMed ID: 7198011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
